GLP-1 drugs are reshaping what gyms sell. As more members lose weight through medication rather than exercise alone, fitness chains and health-tech platforms are building strength-training and muscle-preservation programs around them, responding to evidence that resistance training and adequate protein help offset the lean-mass loss that can accompany drugs like semaglutide and tirzepatide.
This is not a medical guide. This is information, not medical advice. Anyone taking a GLP-1 medication, or considering one, should work with a prescribing clinician on nutrition, exercise, and dosing — the numbers below describe an industry trend and the underlying science, not a personal plan.
Why is the fitness industry moving on this now?
Because GLP-1 use has scaled fast enough to show up in national health data. The Gallup National Health and Well-Being Index found GLP-1 medication use among U.S. adults more than doubled in 18 months, from 5.8% in February 2024 to 12.4% in a survey reported by NPR, with the steepest uptake among adults ages 40-64. Over that same window, Gallup’s tracking showed the U.S. obesity rate easing to 37% in 2025 from a peak of 39.9% three years earlier — a shift researchers linked in part to the drugs’ spread, per NPR’s report on the data.
That volume of new users is exactly the population gyms and fitness apps have historically struggled to retain, which is why the business response has been fast: sell the thing GLP-1 alone doesn’t provide — a way to keep the muscle and function that come with training.
What does the science actually say about muscle loss on these drugs?
It’s real, but it’s more nuanced than a single number. Reporting on MRI-based body-composition research, Medical News Today cites obesity-medicine physicians including Dr. Christopher McGowan and Weill Cornell Medicine’s Dr. Beverly Tchang describing lean-mass loss on GLP-1 drugs as proportional to the amount of weight lost overall, with wide variation between individuals on the same medication — and evidence that some of that lean-mass reduction reflects less fat infiltrated into muscle tissue, not pure muscle loss. The outlet also notes that lean mass, the measurement most studies use, includes organs, bone, and fluid alongside muscle, which is part of why headline figures vary so much between studies.
The underlying pharmacology explains why prescribers keep circling back to muscle: semaglutide and related drugs work primarily by extending fullness signaling in the brain. A National Institutes of Health research summary published in 2026 describes how semaglutide raises a signaling molecule called cAMP in the area postrema, the brainstem region that helps regulate appetite — a mechanism aimed at hunger, not muscle tissue directly, which is consistent with clinicians’ view that muscle loss on these drugs tracks calorie deficit rather than a direct drug effect on muscle. The NIH release is explicit that this was short-term signaling research, not a study of muscle outcomes, and that substantially more research is needed before conclusions extend beyond the lab findings.
Where clinicians agree, per Medical News Today’s reporting, is on the fix: adults on GLP-1 medications are commonly advised to target roughly 1.0-1.2 grams of protein per kilogram of body weight daily and to do resistance training at least twice a week for about 30 minutes, to slow lean-mass loss and preserve strength and function during the deficit.
How are gyms and health platforms building products around this?
Two recent moves show the pattern from different angles — a clinic-and-gym partnership model, and a digital-platform add-on.
| Company | What it launched | How it addresses muscle |
|---|---|---|
| NexgenMD360, with Texas Family Fitness and UFC Gym | Bundled GLP-1 prescribing program with gym access, announced August 2024 | Customized exercise routines through partner gyms as one part of a broader medical-and-lifestyle package; the company’s own release cites client results of 20%+ weight loss, a company claim, not an independently verified outcome |
| Noom, with FitOn | Muscle Defense add-on to the Noom GLP-1 Companion, announced January 2024 | Curated resistance-training videos, expanded protein-forward food logging, and protein-tracking tools; Noom’s release cites data that 68% of GLP-1 users discontinue the medication within a year, framing the muscle-focused build as protection against regaining weight as fat after stopping |
Both are company announcements describing their own products, not independent evaluations of whether either program measurably preserves muscle — a distinction worth holding onto, since press releases are a source for what a company built and claims, not proof that it works as described.
What does this mean for an everyday gym-goer?
If you’re an intermediate or beginner exerciser using a GLP-1 medication, the business trend and the science point the same direction: resistance training isn’t optional cardio-adjacent extra credit while you’re in a drug-assisted deficit, it’s the lever clinicians cite for keeping the strength and function you have. That means prioritizing compound lifts you can progress over time, hitting the protein range your care team sets for you, and treating any new fatigue, joint pain, or rapid strength loss as a reason to loop in your prescribing clinician rather than push through it — GLP-1 dosing, nutrition, and training load are a package your medical team should be adjusting together, not something to self-manage from a fitness article.
FAQ
- Do GLP-1 drugs cause more muscle loss than dieting without medication? Clinicians quoted by Medical News Today describe the lean-mass loss as roughly proportional to overall weight loss, similar to what’s seen with calorie restriction generally, with individual variation rather than a single fixed penalty for using the drugs.
- How much protein do clinicians typically recommend for GLP-1 users? Medical News Today reports a commonly cited range of about 1.0-1.2 grams per kilogram of body weight per day, alongside resistance training — a range from clinicians’ guidance, not a prescription from this site.
- Is a gym’s GLP-1 partnership program independently verified? No. The examples here are company announcements describing their own programs and claims; they are not third-party studies of outcomes.
For a related fitness news perspective, read Two Strength Sessions a Week Is the Floor, Not the Goal.